Keybank National Association OH Has $14.15 Million Stock Position in Gilead Sciences, Inc. $GILD

Keybank National Association OH lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 115,279 shares of the biopharmaceutical company’s stock after purchasing an additional 7,503 shares during the quarter. Keybank National Association OH’s holdings in Gilead Sciences were worth $14,149,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Csenge Advisory Group lifted its stake in Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. boosted its stake in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd boosted its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new stake in Gilead Sciences in the third quarter valued at about $1,274,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 178,640 shares of company stock worth $26,584,250. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $128.84 on Thursday. The stock has a market cap of $159.92 billion, a P/E ratio of 19.03, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock’s 50-day moving average is $140.90 and its 200-day moving average is $132.36. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the previous year, the business posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. BMO Capital Markets raised their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. TD Cowen raised their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Morgan Stanley raised their price objective on Gilead Sciences from $171.00 to $175.00 and gave the company an “overweight” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft raised their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Barclays initiated coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley raised its price target to $175 and maintained an “overweight” rating, implying roughly 36% upside from recent levels—a bullish analyst signal that can support the stock. Morgan Stanley Adjusts Gilead Sciences Price Target to $175
• Positive Sentiment: The U.S. FDA accepted Gilead’s NDA for a once-daily bictegravir + lenacapavir HIV regimen and granted priority review with a PDUFA action date in August—this shortens and de-risks a path to U.S. commercialization if approved. U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment
• Positive Sentiment: Gilead completed its acquisition of Arcellx for about $7.8B, adding the anito-cel cell therapy to its oncology portfolio—this expands growth optionality in cell therapy ahead of potential commercial launches. Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
• Positive Sentiment: Technical analysts noted Gilead is retesting a long-term breakout (an 11-year cup base), arguing upside of ~35% is possible if the breakout holds—this can attract momentum and technical buying. Gilead Sciences Crosses Critical Breakout Level
• Neutral Sentiment: Several market pieces referenced broader biotech/healthcare dynamics (Amgen earnings context; IBB ETF discussion) that may influence sector flows into or out of Gilead but are not Gilead-specific catalysts. Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities—this raises governance and IP-policy scrutiny that could create disclosure/headline risk and pressure valuation around future exclusivity-derived revenue. AHF’s Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.